-

Aldevron Now Offering a CRISPR Ribonucleoprotein Manufacturing Service for Clinical Applications

FARGO, N.D.--(BUSINESS WIRE)--Aldevron, a global leader in the production of plasmid DNA, mRNA and proteins, is now offering a GMP ribonucleoprotein (RNP) manufacturing service. This new platform is designed to deliver clinical grade, ready-to-use RNP complex generated from a CRISPR nuclease and guide RNA (gRNA).

The company developed this platform process for manufacturing RNP complexes using its off-the-shelf GMP-grade CRISPR proteins. Aldevron introduced catalog GMP CRISPR proteins in 2017, an industry first.

Aldevron can use both wild-type SpCas9 and high-fidelity SpyFi™ Cas9 nucleases for RNP manufacturing, and also can custom manufacture unique nucleases. In addition, the platform includes a robust set of analytical methods to help characterize the RNP final product, including nuclease activity and quantification of bound and unbound components post-RNP complex generation.

“Our clients were searching for a one-reagent solution, and that is what GMP RNPs provide,” said Tom Foti, President of Aldevron’s Protein Business Unit. “We have created unique methods to manufacture and characterize RNP complexes produced from GMP CRISPR nucleases and guide RNAs. Our clients will use these RNPs to help create the future of genetic medicines with the launch of novel cell and gene therapies.”

There are three main CRISPR delivery formats: virus, RNA and RNP. RNPs provide a delivery strategy that circumvents transcription and translation. This makes them immediately active and quickly degraded, which reduces the risk of off-target cutting activity. RNPs are also highly titratable, which allows for precise dosage with controlled and efficient delivery to cells that are difficult to transduce with viruses.

About Aldevron

Aldevron serves the biotechnology industry with the custom production of biologics. Thousands of clients use Aldevron-produced plasmid DNA, RNA and gene editing enzymes for projects ranging from research to clinical to commercial applications. Aldevron specializes in GMP manufacturing and is known for inventing the GMP-Source® quality system. Company headquarters are in Fargo, N.D., with additional facilities in Madison, Wisc., and Freiburg, Germany. For more information visit https://www.aldevron.com/.

Contacts

Ellen Shafer
Senior Director of Marketing and Communications
ellen.shafer@aldevron.com
701.297.9256

Aldevron

Details
Headquarters: Fargo, ND, USA
CEO: Kevin Ballinger
Employees: 500+
Organization: PRI

Release Versions

Contacts

Ellen Shafer
Senior Director of Marketing and Communications
ellen.shafer@aldevron.com
701.297.9256

Social Media Profiles
More News From Aldevron

Aldevron Expands Commercial Leadership Team With Addition of Two Industry Veterans

FARGO, N.D.--(BUSINESS WIRE)--Aldevron, the world’s leading biomanufacturer of plasmid DNA, mRNA and proteins, is expanding its commercial leadership with the addition of Beth Thompson-Webb as Chief Commercial Officer and Todd Howren as Vice President of Sales. Thompson-Webb will be responsible for leading Aldevron’s worldwide sales and marketing strategy where she will utilize her 30 years of industry experience to drive strategic growth and service initiatives. Thompson-Webb will report to Ke...

Aldevron Adds Self-Amplifying RNA to its Product Portfolio

FARGO, N.D.--(BUSINESS WIRE)--Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins and mRNA for the biotech industry, announced today the addition of three reporter Self-amplifying RNA (saRNA) products to its growing catalog: AldGFP saRNA™, AldSEAP saRNA™ and AldnLUC saRNA™. Alphavirus-derived saRNA encodes nonstructural proteins that enable self-replication, thereby allowing lower doses for genetic medicines and vaccines, and saRNA is being used to suppo...

Aldevron Now Offering AAV Rep/Cap Plasmids for Viral Vector Production

FARGO, N.D.--(BUSINESS WIRE)--Aldevron announced today the immediate availability of rep/cap plasmids pALD-AAV2, AAV5 and AAV6 to support AAV viral vector manufacturing. All three rep/cap plasmids are immediately available at Research Grade. Additionally, pALD-AAV6 is immediately available at the GMP-Source® quality level, while pALD-AAV2 and pALD-AAV5 will be made available based on market demand. The plasmids are royalty free for all applications in support of pre-clinical activities through...
Back to Newsroom